LB Pharmaceuticals

tenant

drug

Psychiatric interview

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

OTHER

Pre-approval / investigational in the US

Developed by Hospital Center Alpes-Isère

1 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

OTHER

Indications

Investigational (via trials)

Schizophrenia Bipolar Disorder Schizophrenia Borderline Personality Disorder Social Function Self-stigma Bipolar Disorder Borderline Personality Disorder Social Adjustment

Trials

1

Assessment of the Effectiveness of the NECT Program

NCT03972735—Unknown

KOLs & investigators

1

Julien JD DUBREUCQ, MD

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

Hospital Center Alpes-Isère

company

trial

Assessment of the Effectiveness of the NECT Program

NA

trial

indication

indication

Bipolar Disorder

indication

indication

Borderline Personality Disorder

indication

KOL

Julien JD DUBREUCQ, MD

KOL score —

person